7Baggers

Ligand Pharmaceuticals Quarterly Cash Flow Statements Chart

Quarterly
 | 
Annual
 
 Stock-Based Compensation  
 Operating Cash Flow  
 Investing Cash Flow  
 Financing Cash Flow  
 Free Cash Flow  
 Capital Expenditure  
20200331 20200630 20200930 20201231 20210930 20211231 20220331 20220630 20220930 20221231 20230331 20230630 20230930 20231231 20240331 20240630 20240930 20241231 20250331 20250630 -25.66-14.35-3.058.2519.5630.8642.1753.47Milllion

Ligand Pharmaceuticals Quarterly Cash Flow Statements Table

Quarterly
 | 
Annual
 
Unit: USD2025-06-30 2025-03-31 2024-12-31 2024-09-30 2024-06-30 2024-03-31 2023-12-31 2023-09-30 2023-06-30 2023-03-31 2022-12-31 2022-09-30 2022-06-30 2022-03-31 2021-12-31 2021-09-30 2020-12-31 2020-09-30 2020-06-30 2020-03-31 2019-12-31 2019-09-30 2019-06-30 2019-03-31 2018-12-31 2018-09-30 2018-06-30 2018-03-31 2017-12-31 2017-09-30 2017-06-30 2017-03-31 2016-12-31 2016-09-30 2016-06-30 2016-03-31 2015-12-31 2015-09-30 2015-06-30 2015-03-31 2014-12-31 2014-09-30 2014-06-30 2014-03-31 2013-12-31 2013-09-30 2013-06-30 2013-03-31 2012-12-31 2012-09-30 2012-06-30 2012-03-31 2011-12-31 2011-09-30 2011-06-30 2011-03-31 2010-12-31 2010-09-30 2010-06-30 2010-03-31 2009-12-31 2009-09-30 2009-06-30 2009-03-31 2008-12-31 2008-09-30 2008-06-30 2008-03-31 2007-12-31 2007-09-30 2007-06-30 2007-03-31 2006-12-31 2006-09-30 2006-06-30 2006-03-31 2005-12-31 2005-09-30 2005-06-30 2005-03-31 2004-06-30 2004-03-31 2003-12-31 2003-09-30 2003-06-30 2003-03-31 2002-12-31 
                                                                                         
  cash flows from operating activities:                                                                                       
  net income4,847,000 -42,451,000 -31,088,000 -7,172,000 -51,911,000 86,139,000 18,188,000 -10,273,000 2,290,000 41,949,000 -17,485,000 404,000 -895,000 -15,385,000 -5,416,000 13,723,000 5,761,000 -6,701,000 22,086,000 -24,131,000 -7,365,000 -15,251,000 -14,419,000 666,337,000 -42,482,000 67,362,000 73,162,000 45,279,000 -7,010,000 8,429,000 6,058,000 5,079,000            2,097,000 1,869,000 1,965,000 6,091,000 1,495,000 1,063,000 -707,000 -2,267,000 1,384,000 5,502,000 -3,902,000 -914,000 9,490,000 4,503,000 -11,842,000 -284,000 -2,750,000 3,036,000 1,800,000 -1,668,000 -5,116,000 -69,627,000 -18,125,000 -6,429,000 -3,933,000 5,938,000 1,248,000 181,000 274,321,000 141,364,000 -14,920,000 -15,958,000 -142,229,000 -2,722,000 -6,281,000 -8,924,000 -18,472,000 -14,216,000 -13,139,000 5,943,000 -11,088,000 -11,997,000 -20,320,000 -6,728,000 
  adjustments to reconcile net income to net cash from operating activities:                                                                                       
  change in estimated fair value of contingent liabilities52,000 1,879,000 -310,000 -207,000 1,233,000 -33,000 -397,000 24,000 778,000 -670,000 630,000 -112,000 -231,000 -1,035,000 2,415,000 -5,875,000 1,360,000 -26,000 1,000 -372,000                                                                    
  depreciation of fixed assets and amortization of intangible assets8,522,000 8,770,000                                                                                      
  accretion of short-term investments                                                                                       
  amortization of debt discount and issuance fees125,000 136,000 172,000 134,000 96,000 84,000 81,000 0 64,000 95,000 95,000 138,000 175,000 326,000 3,829,000 3,790,000 5,334,000 5,301,000 5,239,000 7,203,000 7,426,000 7,563,000 7,553,000 7,446,000 18,799,000 9,700,000 12,437,000 3,018,000 2,972,000 2,927,000 2,882,000 2,838,000 2,795,000 2,752,000 2,710,000 2,668,000 2,628,000 2,588,000 2,549,000 2,509,000 2,471,000                                               
  non-cash income from financial royalty assets-427,000 -461,000 -780,000                                                                                     
  cecl adjustment to financial royalty assets-420,000 -330,000 -852,000 797,000 -1,419,000 -2,841,000                                                                                  
  impairment loss of financial royalty assets  4,081,000 0                                                                                    
  gain on derivative instruments71,000 174,000   -1,500,000 -196,000                                                                                  
  losses from equity method investment in primrose bio  1,245,000 1,194,000 8,030,000 2,352,000                                                                                  
  fair value adjustment to primrose bio securities investments  0 29,000                                                                                    
  share-based compensation9,997,000 7,836,000 7,524,000 15,171,000 11,060,000 7,334,000 5,721,000 6,884,000 7,207,000 5,931,000 29,145,000 12,597,000 9,499,000 9,044,000 10,408,000 9,754,000 9,975,000 7,740,000 7,359,000 5,653,000 6,300,000 6,297,000 6,571,000 5,347,000 6,009,000                     1,533,000 1,492,000 1,124,000  1,013,000                                      
  deferred income taxes-325,000 -8,844,000 -12,692,000 -1,988,000 -20,666,000 19,546,000 4,935,000 8,007,000 -10,000,000 8,754,000 46,293,000 -12,645,000 3,255,000 -16,180,000 -389,000 1,537,000 258,000 -10,421,000 1,529,000 -10,419,000 17,063,000 2,105,000 -6,602,000 62,263,000 -14,410,000 11,886,000 22,401,000 9,862,000 37,663,000 3,631,000 2,206,000 1,018,000 10,350,000 160,000 -3,914,000 4,101,000 -2,624,000 -217,257,000 262,000 6,000 294,000 110,000 -47,000 53,000 137,000 61,000 110,000 66,000 -1,650,000 143,000 338,000 -35,000 503,000 23,000 125,000 -13,908,000                                
  gain from short-term investments-939,000 12,367,000 31,022,000 -2,407,000 14,256,000 -110,772,000      923,000 1,909,000 12,877,000  -1,938,000                                                                        
  lease amortization expense412,000 571,000 571,000 573,000 504,000 478,000 504,000 334,000 450,000 447,000 986,000 1,481,000                                                                            
  other821,000 915,000 4,600,000 2,765,000 568,000 -210,000 524,000 62,000 -87,000 240,000 410,000 22,000 13,000 -80,000 914,000 63,000 4,182,000 -26,000 -7,167,000 5,668,000 -207,000 2,724,000 1,157,000 -5,130,000  3,452,000 106,000 -522,000  1,000,000          -1,000      0 0 -13,000 144,000 127,000 136,000 85,000 90,000 93,000 73,000 29,000 0 5,000 -10,000 37,000 -14,000 1,000 -23,000 19,000 -24,000 21,000 -8,000 -5,000 163,000 -22,000 -10,000 356,000 -163,000 1,000 -9,000 -8,000 56,000 27,000 24,000 28,000 25,000 39,000 39,000 28,000 477,000 70,000 -119,000 
  changes in operating assets and liabilities:                                                                                       
  accounts receivable-2,765,000 -576,000 -5,665,000 4,793,000 -9,049,000 3,462,000 2,835,000 -7,912,000 1,377,000 1,099,000 34,769,000 -2,658,000 -20,430,000 43,638,000 -19,778,000 -6,179,000 -20,981,000 6,386,000 -3,068,000 -8,398,000 -8,429,000 -1,699,000 6,356,000 29,235,000 -8,164,000 -4,975,000 -4,893,000 -11,512,000 -10,267,000 646,000 -6,380,000 7,643,000 -8,114,000 3,380,000 1,813,000 -5,604,000 -653,000 40,000 1,891,000 5,211,000 -6,822,000 -2,679,000 1,540,000 -2,451,000 3,285,000 -4,808,000 3,923,000 -33,000 -2,432,000 -1,340,000 1,175,000 4,118,000 -4,391,000 -681,000 133,000 1,024,000 -898,000 -95,000 298,000 320,000 1,492,000 -1,060,000 1,665,000 -2,715,000     14,000 36,000 1,219,000 10,268,000 -4,444,000 11,590,000 1,379,000 908,000 3,424,000 -3,362,000 -2,692,000 12,523,000 -3,751,000 4,866,000 -9,128,000 -2,234,000 9,397,000 -4,910,000 -355,000 
  inventory-875,000 -500,000 2,566,000 1,932,000 2,489,000 2,632,000 707,000 -611,000 -13,001,000 2,035,000 1,356,000 962,000 9,696,000 44,000 2,676,000 -777,000 -12,885,000 -11,891,000 5,726,000 1,251,000 -561,000 3,073,000 -1,750,000 -2,823,000 1,204,000 632,000 583,000 -4,978,000 1,142,000 2,301,000 -3,089,000 -1,197,000 2,150,000 -192,000 -3,055,000 853,000 -243,000 375,000 -383,000 -150,000 4,048,000 -254,000 1,132,000 -557,000 560,000 -343,000 327,000 102,000 1,828,000 -493,000 -261,000 -44,000 659,000 634,000 1,618,000 -1,797,000                                
  accounts payable and accrued liabilities-407,000 -2,149,000 11,286,000 2,227,000 1,772,000 -1,382,000 2,757,000 -2,501,000 -4,525,000 -435,000 -2,935,000 3,952,000 -1,649,000 -2,708,000 6,445,000 705,000 -11,139,000 6,985,000 795,000 2,114,000 -3,452,000 406,000 -1,904,000 -1,876,000    321,000 936,000 -496,000 -190,000 -1,963,000 710,000 244,000 979,000 -4,302,000 966,000 -1,886,000 1,560,000 -4,667,000 323,000 265,000 -2,741,000 -1,002,000 -452,000 287,000 -495,000 -2,098,000 -1,792,000 642,000 -145,000 -3,506,000 -5,150,000 1,765,000 -7,755,000 -428,000 788,000 -6,203,000 1,778,000 -9,810,000 -3,053,000 5,084,000 -523,000 -12,497,000 5,881,000 -7,505,000 -1,305,000 -4,409,000 -6,859,000 -11,377,000 -20,665,000 -12,988,000 -21,887,000 -8,627,000 17,786,000 -14,912,000 11,401,000 6,406,000 -3,162,000 -958,000 4,163,000 3,164,000 10,512,000 9,321,000 -1,943,000 6,629,000 3,430,000 
  income tax receivable and payable2,423,000 335,000  -9,093,000 953,000 7,533,000  -10,183,000 11,387,000 4,614,000  6,100,000 -2,982,000 11,993,000  -1,690,000                                                                        
  deferred revenue-285,000 -293,000 -136,000 -232,000 -400,000 -540,000 193,000   -98,000 -1,099,000 -2,928,000 199,000 -2,453,000 2,826,000 -6,091,000                 -1,505,000 1,384,000 100,000 13,000 -2,109,000 -8,000 -27,000 -83,000 82,000 22,000 92,000 -116,000 -220,000 -116,000 -144,000 -174,000 -141,000 -138,000 -963,000 -609,000 3,406,000 -29,000 -1,244,000 27,000 0 -2,663,000 -1,660,000 -1,615,000 -7,306,000 -2,890,000 -1,892,000 -2,214,000     0 0 0 -8,657,000 -22,121,000 -35,979,000 -7,943,000 -6,576,000 -782,000 4,774,000 357,000 332,000 -43,000 -295,000 -1,015,000 -702,000 -790,000 -351,000 -2,188,000 
  other assets and liabilities-4,262,000 -1,985,000 634,000 7,494,000 -3,375,000 -3,462,000 -8,966,000 -769,000 -812,000 682,000 8,013,000 -417,000 -1,021,000 -233,000  -5,894,000                                                                        
  net cash from operating activities15,799,000 -25,445,000 28,471,000 36,530,000 13,314,000 18,732,000 8,065,000 7,646,000 -82,000 33,948,000 53,472,000 20,489,000 11,878,000 52,011,000 27,642,000 20,025,000    16,922,000 -7,339,000 -6,197,000 -61,058,000 45,258,000 32,572,000 27,082,000 73,644,000 60,761,000 31,310,000 27,650,000 10,386,000 24,222,000 20,993,000 18,523,000 10,371,000 13,114,000 13,665,000 10,437,000 10,046,000 7,579,000 10,246,000 3,735,000 4,008,000 2,577,000 12,034,000 -359,000 6,937,000 2,078,000 2,172,000 -910,000 -732,000 -369,000 7,017,000 -1,055,000 -8,045,000 911,000 -1,300,000 -7,674,000 -2,217,000 -15,876,000 -1,289,000 -11,341,000 2,950,000 -24,121,000 6,193,000 -13,448,000 -3,971,000 -9,399,000 -8,787,000 -14,231,000 -29,360,000 -45,349,000 -84,069,000 -28,021,000 -6,447,000 -19,984,000 12,072,000 6,795,000 -7,905,000 -2,597,000 -11,636,000 -3,616,000 9,176,000 -2,611,000 3,456,000 -9,747,000 -9,562,000 
  capex-214,000 -214,000 0 -596,000 -408,000 -105,000 0 -487,000 -203,000 -2,414,000 0 -4,329,000 -6,588,000 -4,875,000 0 -1,772,000    0 0 0 0 0 0 0 0 0 -1,936,000 -21,000 -112,000 -87,000 -67,000 -762,000 -783,000 -238,000 -66,000 0 -17,000 -10,000 0 0 0 -6,000 0 -105,000 -121,000 -37,000 38,000 -372,000 -242,000 -19,000 0 0 0 -5,000 0 -5,000 -9,000 -56,000 15,000 -217,000 -106,000 -214,000 -41,000 -69,000 -189,000 -196,000 -71,000 -38,000 -245,000 -86,000 -191,000 -918,000 -484,000 -190,000 -826,000 -625,000 -548,000 -597,000 -1,069,000 -952,000 -1,542,000 -796,000 -207,000 -238,000 -281,000 
  free cash flows15,585,000 -25,659,000 28,471,000 35,934,000 12,906,000 18,627,000 8,065,000 7,159,000 -285,000 31,534,000 53,472,000 16,160,000 5,290,000 47,136,000 27,642,000 18,253,000    16,922,000 -7,339,000 -6,197,000 -61,058,000 45,258,000 32,572,000 27,082,000 73,644,000 60,761,000 29,374,000 27,629,000 10,274,000 24,135,000 20,926,000 17,761,000 9,588,000 12,876,000 13,599,000 10,437,000 10,029,000 7,569,000 10,246,000 3,735,000 4,008,000 2,571,000 12,034,000 -464,000 6,816,000 2,041,000 2,210,000 -1,282,000 -974,000 -388,000 7,017,000 -1,055,000 -8,045,000 906,000 -1,300,000 -7,679,000 -2,226,000 -15,932,000 -1,274,000 -11,558,000 2,844,000 -24,335,000 6,152,000 -13,517,000 -4,160,000 -9,595,000 -8,858,000 -14,269,000 -29,605,000 -45,435,000 -84,260,000 -28,939,000 -6,931,000 -20,174,000 11,246,000 6,170,000 -8,453,000 -3,194,000 -12,705,000 -4,568,000 7,634,000 -3,407,000 3,249,000 -9,985,000 -9,843,000 
  cash flows from investing activities:                                                                                       
  acquisition of financial royalty assets0 -1,821,000 0                                                                                     
  proceeds from financial royalty assets2,030,000 3,149,000 2,537,000 685,000 2,265,000 1,942,000                                                                                  
  purchases of property and equipment-214,000 -214,000                           -1,936,000 -21,000 -112,000 -87,000 -67,000 -762,000 -783,000 -238,000 -66,000 0 -17,000 -10,000    -6,000  -105,000 -121,000 -37,000       0 -5,000 0 -5,000 -9,000 -56,000 15,000 -217,000 -106,000 -214,000 -41,000 -69,000 -189,000 -196,000 -71,000 -38,000 -245,000 -86,000 -191,000 -918,000 -484,000 -190,000 -826,000 -625,000 -548,000 -597,000 -1,069,000 -952,000 -1,542,000 -796,000 -207,000 -238,000 -281,000 
  purchases of short-term investments-63,343,000 -59,374,000                                                   0 0 -5,000,000 -5,000,000 -1,791,000 -1,932,000 0 -31,861,000 0 0 -21,549,000 -11,257,000 -5,997,000 -3,515,000 -36,257,000 -22,601,000 -1,939,000 -17,065,000   -59,000 -5,630,000 -7,968,000 -4,726,000 -1,203,000 -3,404,000 -3,424,000 -21,425,000 -17,505,000 -8,375,000 -27,149,000 -378,000 -168,000 -331,000 -4,178,000 
  proceeds from sale of short-term investments0 38,414,000 39,804,000 90,655,000 37,989,000 60,919,000 52,447,000 7,486,000 44,600,000 44,232,000 7,009,000 24,998,000 44,688,000 132,866,000 1,765,000 1,817,000 5,243,000 209,865,000 0 179,431,000 391,695,000 100,458,000 43,383,000 341,000 55,949,000 63,202,000 500,000 12,291,000 3,595,000 122,000 65,549,000 17,719,000 1,209,000 1,310,000 1,807,000 20,270,000 10,359,000 3,302,000 1,919,000 459,000 846,000 340,000 530,000 626,000     0 1,500,000 0 8,500,000 0 0 5,458,000 13,888,000 2,734,000 10,639,000 5,924,000 34,743,000 2,001,000 13,044,000 17,316,000 15,400,000 12,752,000 -101,000 10,352,000 9,012,000 12,134,000 -237,000 1,091,000 7,128,000 8,591,000 2,778,000 6,301,000 7,884,000 6,575,000 15,065,000 6,738,000 2,945,000 548,000 16,797,000 760,000 4,289,000 3,781,000 1,223,000 3,450,000 
  proceeds from maturity of short-term investments50,860,000 32,360,000 5,380,000 4,140,000 9,067,000 14,544,000 7,461,000 17,275,000 12,201,000 8,465,000 0 0 0 24,830,000 30,005,000 2,500,000 55,000,000 136,750,000 155,400,000 297,005,000 220,000,000 483,845,000 458,359,000 332,647,000 511,183,000 271,515,000 55,850,000 54,325,000 33,762,000 24,000,000 21,835,000 30,052,000 5,180,000 30,171,000 35,122,000 48,401,000 34,267,000                                                   
  cash paid for investment in primrose bio  0 0 0 -998,000 -14,000                                                                                 
  cash paid for palvella notes receivable  0 0                                                                                    
  cash paid for the agenus transaction  0 0                                                                                    
  purchase of castle creek derivatives                                                                                       
  net cash from investing activities-10,667,000 4,894,000  -46,507,000 -54,759,000 -3,775,000  -19,503,000 7,556,000 10,549,000 -7,284,000 19,176,000 37,851,000 113,881,000 -35,713,000 -18,217,000 -382,202,000 332,071,000 -26,757,000 308,536,000 -63,179,000 169,517,000 265,803,000 94,777,000 275,302,000 -78,252,000 -586,738,000 -33,581,000 -36,174,000   -30,666,000 -86,727,000 5,078,000 18,217,000 -79,760,000 -11,477,000 -26,365,000 -72,223,000 -2,797,000 -1,711,000 72,000 610,000 -998,000 -1,003,000 -245,000 -3,692,000 -34,000   -242,000 3,945,000 -2,279,000 -137,000 453,000 -23,169,000 1,028,000 8,276,000 1,356,000 3,880,000 12,074,000 13,052,000 -4,231,000 3,873,000 10,960,000 -3,597,000 -26,010,000 -5,777,000 20,879,000 -9,649,000 6,323,000 326,284,000 199,746,000 -3,744,000 -2,132,000 2,995,000 5,120,000 11,055,000 -10,318,000 -39,575,000 -18,479,000 6,397,000 -27,767,000 3,071,000 3,471,000 -3,394,000 -102,277,000 
  cash flows from financing activities:                                                                                       
  payments under finance lease obligations-7,000 -7,000 -6,000 -10,000 -4,000 -5,000                                                                                  
  net proceeds from stock option exercises and espp8,239,000 4,222,000 19,337,000 21,395,000 9,552,000 15,304,000 6,526,000 3,387,000 9,142,000 3,393,000 1,401,000 820,000 664,000 347,000 4,279,000 1,900,000 558,000 909,000 1,129,000 421,000 141,000 213,000 739,000 1,904,000 1,323,000 7,011,000 2,933,000 8,916,000 653,000 1,494,000 2,015,000 355,000 1,807,000 2,126,000 1,469,000 1,013,000  1,949,000 4,649,000 781,000                                                
  taxes paid related to net share settlement of equity awards-145,000 -8,891,000 -1,935,000 -125,000 0 -3,076,000 -257,000 -103,000 -32,000 -4,155,000 -2,218,000 -96,000 -60,000 -5,862,000 -115,000 -2,000 -52,000 0 0 -1,429,000 -1,512,000 -13,000 2,000 -2,895,000 -108,000 -223,000 363,000 -3,797,000 -5,942,000 -90,000 -2,020,000 -2,022,000 0                                                       
  cash paid for debt issuance costs-2,000 -71,000 -118,000 -210,000 -57,000 -41,000                                                                                  
  proceeds from pelthos investors                                                                                       
  net cash from financing activities14,995,000 -4,747,000  55,080,000 9,491,000 12,182,000 5,315,000 3,270,000 -67,757,000 -775,000 -5,298,000 -40,829,000 -59,442,000 -170,421,000 4,164,000 -385,000 -27,529,000 -3,706,000 -5,000 -279,305,000 -83,693,000 -211,312,000 -37,591,000 -152,576,000 -347,085,000    -7,255,000 1,404,000 -5,000 -1,667,000 -2,094,000 1,629,000 1,469,000 511,000 1,470,000 1,460,000 4,649,000 781,000 -28,995,000 162,319,000 -3,058,000 -241,000 -2,663,000 -2,048,000 -2,359,000 -9,388,000 3,235,000 1,439,000 82,000 -840,000 52,000 2,000 5,000,000 24,945,000 -178,000 -41,000 52,000 8,000 87,000 -100,000 -90,000 -3,585,000 -201,000 -331,000 -385,000 -2,093,000 -4,581,000 -10,430,000 -277,263,000 -35,425,000 32,695,000 179,000 386,000 41,000 -24,000 -842,000 -153,000 818,000 6,477,000 3,747,000 4,619,000 48,294,000 4,342,000 -16,303,000 131,085,000 
  effect of exchange rate changes on cash and cash equivalents2,292,000 1,058,000 -1,548,000                                                                                     
  net decrease in cash and cash equivalents, including cash and cash equivalents classified within assets held for sale                                                                                       
  less: net increase in cash and cash equivalents classified within assets held for sale-2,739,000 -78,000                                                                                      
  net decrease in cash and cash equivalents                               -8,111,000  25,230,000                        561,000 -809,000 -11,988,000  1,611,000 -1,371,000 -23,833,000  -17,376,000    -34,310,000    -31,586,000 -8,193,000 -16,948,000  17,008,000        -29,444,000  
  cash and cash equivalents at beginning of period0 72,307,000  0 0 22,954,000                     0 20,620,000  0 0 18,752,000  0 0 97,428,000  0 0 160,203,000  0 0 11,639,000  0 0 12,381,000  0 0 7,041,000  0 0 3,346,000  0 0 16,032,000  0 0 28,753,000  0 0 76,812,000  0 0 158,401,000  0 0 66,756,000  0 0 92,310,000 0 59,030,000  0 0 42,423,000  
  cash and cash equivalents at end of period19,680,000 47,989,000  45,480,000 -31,954,000 50,093,000                     100,435,000 51,024,000  -27,484,000 49,582,000 10,641,000  25,230,000 30,057,000 31,293,000  -14,468,000 -57,528,000 165,766,000  166,126,000 1,560,000 12,977,000  -2,652,000 886,000 5,037,000  -1,839,000 -892,000 9,777,000  -1,190,000 -2,592,000 6,033,000  561,000 -809,000 4,044,000  1,611,000 -1,371,000 4,920,000  -17,376,000 -30,366,000 59,543,000  -34,310,000 -300,300,000 403,911,000  -31,586,000 -8,193,000 49,808,000  17,008,000 -18,376,000 50,956,000 -23,638,000 65,558,000  48,754,000 11,269,000 12,979,000  
  amortization/accretion of premium (discount) on investments -839,000                                                                                      
  changes in operating assets and liabilities, net of acquisitions:                                                                                       
  purchases of derivatives -7,620,000                                                                                      
  net increase in cash and cash equivalents, including cash and cash equivalents classified within assets held for sale -24,240,000                                                                                      
  net increase in cash and cash equivalents -24,318,000 8,688,000 45,480,000 -31,954,000 27,139,000                   -39,211,000 7,747,000 100,435,000 30,404,000 -12,119,000 -27,484,000      -66,135,000 3,658,000 -14,468,000 -57,528,000 5,563,000 -20,460,000 166,126,000 1,560,000 1,338,000 8,368,000 -2,652,000 886,000 -7,344,000 5,335,000 -1,839,000 -892,000 2,736,000   -2,592,000 2,687,000            -17,269,000    245,510,000        -41,354,000  6,528,000 -13,972,000 48,754,000   19,246,000 
  gain on sale of pelican      0                                                                                 
  gain on debt extinguishment          0 -866,000 -1,794,000 -1,532,000  128,000  0 0 -659,000                                                                    
  changes in operating assets and liabilities, net of acquisitions and dispositions:                                                                                       
  other economic rights                    0 0                                                                  
  income taxes receivable and payable                                                                                       
  cash paid for equity method investment - nucorion                                                                                       
  cash paid for novan acquisition, net of restricted cash received      0                                                                                 
  cash paid for apeiron acquisition, net of cash received  0                                                                                     
  cash paid for invios investment  0                                                                                     
  net proceeds from viking share collar and viking share put                                                                                       
  net cash from (provided by) investing activities                                                                                       
  proceeds from common stock issuance, net of commissions and fees                                                                                       
  net cash transferred to omniab at omniab separation                                                                                       
  repayment at maturity/repurchase of 2023 notes      0 0                                                                                
  cash paid for transaction costs related to omniab transactions                                                                                       
  proceeds from bond hedge settlement                                                                                       
  payments to cvr holders          -585,000 456,000 0 -1,416,000 0 0 0 -525,000 0 -1,800,000 0                            0 -3,500,000 0 -4,549,000                                    
  net cash from (used) in financing activities                                                                                       
  cash and cash equivalents at beginning of year                                                                                       
  cash and cash equivalents at end of year                                                                                       
  supplemental disclosure of cash flow information                                                                                       
  interest paid           101,000 679,000 359,000  3,000                           102,000 110,000  321,000 254,000 991,000 598,000 552,000 671,000 631,000 714,000            57,000 43,000 51,000 78,000 231,000 44,000 90,000 1,146,000 4,509,000 339,000 4,427,000 517,000 5,852,000 361,000 4,880,000 328,000 5,001,000 300,000 4,930,000 207,000 4,532,000 132,000 151,000 
  taxes paid           6,610,000    168,000                                  0 -2,000 17,000 12,000            45,000 3,000 91,000 1,000 2,075,000 1,641,000 3,613,000 1,042,000                
  acquisitions:                                                                                       
  fair value of tangible assets acquired, net of cash and restricted cash received                                                                                       
  goodwill                                                                                       
  intangible assets                                                                                       
  financial royalty assets                                                                                       
  liabilities assumed                                                                                       
  net cash paid for acquisitions                                                                                       
  supplemental schedule of non-cash investing and financing activities:                                                                                       
  accrued primrose transaction costs                                                                                       
  addition of right-of-use assets and lease liabilities                                                                                       
  accrued royalty from financial royalty assets                                                                                       
  accrued purchases of financial royalty assets                                                                                       
  accrued debt issuance costs                                                                                       
  accrued fixed asset purchases        392,000 140,000  -174,000 1,226,000 2,574,000  198,000                                                                        
  unrealized gain on available-for-sale investments, net of tax                                                                                       
  depreciation and amortization of intangible assets   8,994,000 8,853,000 8,765,000  8,611,000 9,495,000 9,499,000  13,478,000 13,266,000 13,655,000  12,723,000 13,046,000 4,776,000 4,447,000 3,422,000                                                                    
  amortization of premium on investments   -138,000 -430,000 -157,000  -279,000 -377,000 -282,000  31,000 -7,000 51,000                                                                          
  loss on derivative assets                                                                                       
  purchase of short-term investments   -31,554,000 -24,441,000 -77,634,000  -18,273,000 -49,125,000 -39,864,000  -580,000 -282,000 -38,190,000  -20,762,000  -290,000 -169,352,000 -167,374,000  -401,312,000 -233,507,000 -1,047,767,000  -412,507,000 -646,826,000 -98,957,000  -80,839,000 -50,930,000 -73,352,000  -23,217,000 0 -49,892,000  -51,356,000                                                  
  purchase of property and equipment   -596,000 -408,000 -105,000  -487,000 -203,000 -2,414,000  -4,329,000 -6,588,000 -4,875,000  -1,772,000                                                                        
  proceeds from atm sales, net of commissions and fees                                                                                       
  changes in operating assets and liabilities, net of acquisition:                                                                                       
  purchase of financial royalty assets    -1,731,000 -2,443,000                                                                                  
  operating activities                                                                                       
  gain short-term investments                                                                                       
  amortization of commercial license and other economic rights              -221,000 -110,000 -230,000 -228,000 -225,000 2,958,000                                                                    
  adjustment to credit loss reserves of commercial license rights                                                                                       
  impairment loss of commercial license rights      0                                                                                 
  investing activities                                                                                       
  purchase of commercial license rights                                0 -4,000   0 0       0 0                                          
  proceeds from commercial license rights      69,000 136,000 83,000 130,000                                                                              
  net cash (used) provided in investing activities                                                                                       
  financing activities                                                                                       
  net cash transferred to omniab at separation                                                                                       
  cash paid for omniab transaction costs                                                                                       
  repurchase of warrants                                                                                       
  net increase in cash, cash equivalents, and restricted cash                                                                                       
  cash paid during the year:                                                                                       
  acquisition:                                                                                       
  deferred tax asset                                                                                       
  net cash paid for novan                                                                                       
  accrued royalty from commercial license rights                                                                                       
  accrued commercial license rights purchases                                                                                       
  accrued inventory purchases        -106,000 2,752,000  -1,485,000 8,855,000 306,000  -7,727,000                              -770,000                                          
  unrealized gain on available-for-sale investments                                                                                       
  amortization of commercial license rights       -69,000 -435,000 -379,000  27,000 -179,000 -11,000                                                                          
  cecl adjustment to commercial license rights                                                                                       
  (gain) income from short-term investments       13,184,000 -3,991,000 -39,533,000                                                                              
  other current assets                            3,000 85,000 -431,000 745,000 567,000 620,000 -645,000 16,000 489,000 24,000 -907,000 445,000 189,000 -479,000 -254,000 118,000 553,000 -301,000 -225,000 -157,000 186,000 1,012,000 -221,000 -462,000 319,000 205,000 -265,000 4,605,000 -3,953,000 88,000 -113,000 47,000 -1,081,000 -275,000 106,000 802,000 3,903,000 -1,595,000 586,000 2,048,000 -2,212,000 -231,000 388,000 3,459,000 4,605,000 12,212,000 -10,092,000 -144,000 -3,078,000 252,000 4,152,000 637,000 519,000 46,000 -622,000 -553,000 3,913,000 760,000 -4,473,000 
  proceeds from convertible bond hedge settlement               2,083,000                                                                        
  payments for omniab transaction costs           -3,965,000                                                                            
  net decrease in cash, cash equivalents and restricted cash       -8,587,000    -1,164,000 -9,713,000 -4,529,000                                                                          
  cash, cash equivalents and restricted cash at beginning of period       0 0 45,006,000  0 0 19,522,000  0  0 0 72,273,000  0 0 119,780,000                                                                
  cash, cash equivalents and restricted cash at end of period       -8,587,000 -60,283,000 88,728,000  -1,164,000 -9,713,000 14,993,000  1,423,000  341,220,000 -2,371,000 118,257,000  -48,087,000 167,031,000 107,369,000                                                                
  cash paid for equity method investment          0 0 0 -750,000   0    0                                                                   
  supplemental disclosure of cash flow information:                                                                                       
  supplemental schedule of non-cash activity:                                                                                       
  unrealized gain on afs investments, net of tax        -32,000 49,000                                                                              
  repurchase of 2023 notes           -37,646,000 -59,947,000 -163,356,000  -2,379,000  0 0 -203,210,000                                                                    
  payments under financing lease obligations         -13,000  -15,000 -14,000 -13,000  0                                                                        
  net increase in cash, cash equivalents and restricted cash         43,722,000      1,423,000  341,220,000 -2,371,000 45,984,000  -48,087,000 167,031,000 -12,411,000                                                                
  gain from sale of vernalis r&d                                                                                       
  income taxes receivable                                                                                       
  cash paid for acquisition, net of cash and restricted cash acquired                                                                                       
  proceeds on sale of vernalis r&d                                                                                       
  repayment of debt                    0    -195,889,000 0               -2,000 -2,417,000 -3,511,000 -3,436,000 -3,362,000 -3,291,000 -3,219,000 -9,714,000 0 -1,500,000 0 -8,500,000         0 0 0 -3,443,000     0 0 0 -37,750,000                
  share repurchases                                                    0 0 0 -55,000                                
  payments to convertible bond holders for warrant purchases               -1,987,000                                                                        
  unrealized loss on afs investments           6,000 -35,000 -114,000  -14,000                                                                        
  restricted cash in other current assets                                                                                       
  gain from sale of promacta license                    0 0 0 -812,797,000                                                                
  loss on debt extinguishment                                                                                       
  proceeds from sale of promacta license                    0 0 0 812,797,000                                                                
  payments to convert holders for bond conversion                    0                                                                   
  net decrease in cash, cash equivalents, and restricted cash                                                                                       
  effect of exchange rate changes on cash                 110,000 9,000 -169,000 171,000 -95,000 -123,000 130,000                                                                
  cash, cash equivalents and restricted cash at beginning of year                                                                                       
  cash, cash equivalents and restricted cash at end of year                                                                                       
  operating lease liabilities                                                                                       
  cash paid for acquisition, net of cash acquired                    0            2,000 0 351,000 -92,855,000                                                    
  share repurchase                 0 0 -73,287,000  -181,189,000 -38,332,000 -151,585,000  0 -50,832,000 -1,895,000                                                            
  accrued financing lease payment                                                                                       
  amortization of premium (discount) on investments                 309,000 368,000 830,000    -1,818,000     -169,000 132,000 2,000 -46,000                                                        
  royalties recorded in retained earnings upon adoption of asc 606                        0                                                               
  proceeds received from repayment of viking note receivable                            0    0 0                                                      
  gross proceeds from issuance of 2023 convertible senior notes                        0 0                                                              
  payment of debt issuance costs                        0 0               0                                               
  proceeds from issuance of warrants                        0 0               1,000                                               
  purchase of convertible bond hedge                        0 0               0                                               
  supplemental schedule of non-cash investing and financing activities                                                                                       
  unrealized gain on afs investments                                          -5,127,000 8,222,000  806,000                                          
  purchase of fixed assets recorded in accounts payable                                                                                       
  income from short-term investments                                                                                       
  net cash from (used in ) operating activities                 12,745,000                                                                      
  repayment of 2019 notes                                                                                       
  payments to convertible bond holders for bond conversion                                                                                       
  income tax receivable                  4,592,000 4,081,000                                                                    
  cash paid for acquisition                                                                                       
  gain from investment in viking                   25,456,000  10,520,000 12,365,000 -17,293,000                                                                
  realized gain on sale of short-term investment                            -460,000 -123,000 -182,000 -66,000 -576,000 -1,174,000   -615,000 -1,486,000 -949,000 447,000 -297,000 -273,000                                              
  (gain) loss on equity investment in viking                                                                                       
  non-cash change in estimated fair value of contingent liabilities                     -222,000 -419,000 1,403,000  907,000 1,770,000 960,000  1,336,000 826,000 140,000  957,000 332,000 1,306,000  -2,301,000 7,274,000 3,000  1,619,000 1,313,000 1,948,000 3,965,000 532,000 -2,741,000 1,841,000 2,841,000                                       
  depreciation and amortization                     3,779,000 3,695,000 5,086,000 3,297,000 5,408,000 3,011,000 3,002,000 4,133,000 2,017,000 2,585,000 2,979,000 2,968,000 2,934,000 2,813,000 2,575,000 687,000 644,000 646,000 650,000 659,000 661,000 669,000 668,000 656,000 668,000 669,000 670,000 749,000 638,000 662,000 678,000 691,000 750,000 785,000 564,000                                
  amortization of discount on investments                     -1,454,000            179,000 11,000 320,000  107,000                                                  
  amortization of other economic rights                     4,765,000                                                                  
  changes in operating assets and liabilities, net of effects from acquisition:                                                                                       
  income tax payable                     -30,884,000 -66,542,000 113,997,000                                                                
  gross proceeds from issuance of 2023 notes                                                                                       
  less: income from discontinued operations                                                                                       
  income from continuing operations                            -7,010,000 8,429,000 6,058,000 5,079,000 -3,126,000 645,000 -5,763,000 5,877,000     6,732,000 776,000 1,287,000 2,097,000 1,869,000 1,965,000 3,694,000 1,304,000 2,586,000 -707,000 -4,066,000 -487,000 5,502,000 -3,901,000 -914,000 9,486,000 2,348,000 -11,854,000 -291,000 -2,989,000 2,569,000 1,051,000 -4,475,000 -7,482,000                        
  change in fair value of the convertible debt receivable from viking and warrants                                                                                       
  change in derivative asset and liability fair value                                                                                       
  other long term assets                                                  39,000 175,000 39,000 -4,000 110,000 460,000  41,000 43,000 -456,000  1,000 10,265,000 -202,000                        
  contingent liabilities                        25,000                                                               
  purchase of viking common stock and warrant                                                                                       
  purchase of common stock in equity method investment                                0                                                       
  payments to cvr holders and other contingency payments                        0 0   0 0 0 -4,998,000 -1,722,000 -1,420,000 -189,000 -5,446,000 -1,799,000 -1,278,000 -416,000 -3,247,000 -1,557,000                                               
  stock issued for acquisition, net of issuance cost                                                                                       
  stock and warrant received for repayment of viking notes receivable                                                                                       
  change in fair value of viking warrants                                                                                       
  (gain) / income from investment in viking                                                                                       
  accounts payable, accrued liabilities and other                         -5,497,000                                                              
  cash and cash equivalents and restricted cash at beginning of period                                                                                       
  cash and cash equivalents and restricted cash at end of period                                                                                       
  payments to cvr holders and other contingent payments                                                                                       
  stock-based compensation                          4,812,000 4,555,000 8,998,000 5,248,000 4,624,000 6,045,000 5,203,000 5,331,000 4,241,000 4,118,000 2,947,000 2,836,000 3,761,000 2,914,000 2,475,000 3,702,000 3,026,000 2,067,000        709,000 705,000 950,000 1,244,000 452,000 311,000 557,000 833,000 624,000 924,000 741,000 880,000 820,000 820,000 940,000 851,000 996,000 584,000 866,000 576,000 5,554,000 1,357,000 1,938,000 1,229,000 814,000            
  change in fair value of the viking convertible debt receivable and warrants                          -7,702,000 -748,000  -503,000 153,000 -76,000  -154,000                                                      
  (gain) / income from equity investments                          -32,506,000 -21,183,000                                                            
  royalties recorded in retained earnings upon adoption of asu 606                          0 32,707,000                                                            
  proceeds received from repayment of commercial license rights                             0                                                          
  net cash from provided by financing activities                          613,529,000 3,224,000                                                            
  less: gain from discontinued operations                                  0 731,000         0 0 2,397,000 191,000 -1,523,000 0 1,799,000 1,871,000 0 -1,000 0 4,000 2,155,000 12,000 7,000 239,000 467,000 749,000 2,807,000 2,366,000                        
  gain on deconsolidation of viking                                                                                       
  loss on equity investment in viking                                                                                       
  reduction of cash due to deconsolidation of viking                                                                                       
  gain on disposal of assets                                0                                                       
  income from equity method investment                                                                                       
  other long-term assets                                 11,000 -1,000 -41,000  52,000 -307,000 -291,000  -1,014,000 -255,000 24,000  50,000 57,000 66,000                                        
  purchase of viking common stock and warrants                                 0                                                      
  income from viking                              1,247,000 1,083,000                                                        
  net cash provided (used) in investing activities                                                                                       
  non-cash milestone revenue                                                                                       
  restricted cash                                       661,000                                                
  net cash from operating activities of continuing operations                                        10,246,000 3,735,000 4,008,000 2,577,000 12,034,000 -359,000 6,937,000 2,720,000 2,522,000 -560,000 -732,000 -169,000 7,017,000 -1,055,000 -8,045,000 911,000 -1,278,000 -7,673,000 -2,218,000 -16,138,000 -1,434,000 -11,168,000 4,769,000 -22,806,000                        
  net cash from operating activities of discontinued operations                                            0 0 0 -642,000 -350,000 -350,000       -22,000 -1,000 1,000 262,000 145,000 -173,000 -1,819,000 -1,315,000                        
  gross proceeds from issuance of 2019 convertible senior notes                                        0                                               
  net income including noncontrolling interests                                 645,000 -5,763,000 6,608,000  224,539,000 22,027,000 -89,000  776,000                                              
  adjustments to reconcile net income including noncontrolling interests to net cash from operating activities:                                                                                       
  accretion of note payable                                     0 2,000 14,000 -3,000 56,000 69,000 100,000 96,000 96,000 83,000 142,000                                        
  gain on deconsolidation of viking therapeutics                                                                                       
  income from viking therapeutics                                 1,396,000                                                      
  restricted investments                                     0                                                  
  proceeds from sale of property and equipment                                     0 0 1,000 0 0    0 0 3,000                  2,000    0                  
  gain on write-off of assets                                         0                                              
  purchase of common stock for rsu vesting                                  0 -502,000                                                    
  realized (gain) loss on sale of short-term investment                                   -406,000                                                    
  change in fair value of the convertible debt receivable from viking                                   15,000                                                    
  loss on equity investment in viking therapeutics, inc.                                   1,605,000  2,170,000                                                  
  write-off of acquired in-process research and development                                                            1,000 0                          
  purchase of viking common stock                                    0 0                                                  
  net proceeds from stock option exercises                                          453,000 3,195,000 629,000 1,244,000 775,000 326,000                                        
  non-cash upfront fee                                         0                                              
  gain on deconsolidation of viking therapeutics, inc.                                     0                                                  
  reduction of cash due to deconsolidation of viking therapeutics, inc.                                     0                                                  
  (gain) loss on asset disposal                                                                                       
  other liabilities                                            5,000 17,000 -293,000 -120,000 469,000    4,994,000 -2,493,000 -836,000 -800,000 360,000 -20,000 245,000 -1,300,000 -5,685,000 4,936,000 -1,395,000 -174,000 1,820,000 -686,000 34,000 84,000 485,000 115,000 555,000 -242,000  5,000 -16,000 -3,000 -135,000 -10,000 -12,000 -2,000 0 -600,000      
  proceeds from issuance of debt                                                0 0 0 7,500,000 0 0 5,000,000 25,000,000                                
  proceeds from issuance of common stock                                                  82,000 160,000              25,000 12,000 34,000  260,000 1,232,000 2,857,000  462,000 1,051,000 468,000    773,000  2,733,000      
  write-off of in-process research and development                                             0                                          
  payments to cvr holders and former license holders                                          -50,000 -1,618,000                                            
  supplemental schedule of non-cash activity                                                                                       
  liability for commercial license rights                                             0                                          
  realized (gain) on investment                                           -481,000                                            
  loss on write off of assets                                           109,000                                            
  accretion of deferred gain on sale leaseback                                                    -425,000 -426,000 -425,000 -426,000 -425,000 -426,000 -426,000 -425,000 -426,000 -20,444,000 -491,000 -491,000     -491,000 -491,000                  
  non-cash lease costs                                                    84,000 0 -45,000 -90,000  9,655,000 -17,000 -47,000  -156,000 239,000 262,000  827,000 0 4,148,000                    
  gain on asset disposal                                                                                       
  acquisition of cydex, net of cash acquired                                                    0 0 0 -32,024,000                                
  purchases of property, equipment and building                                                38,000 -372,000 -242,000 -19,000                                    
  proceeds from sale of property, and equipment and building                                                3,000 4,000 0 13,000                                    
  net proceeds from employee stock purchase program                                                                                       
  net proceeds from issuance of common stock                                                     2,000   -87,000 -2,000 94,000 18,000 168,000 -6,000 45,000 21,000             18,000 -8,000       554,000 136,000  
  net proceeds from employee stock purchase plan                                             -1,000                                          
  changes in operating assets and liabilities,:                                                                                       
  realized gain on investment                                                   -17,000 0 0 29,000 -23,000 -22,000 -21,000 127,000 -691,000                            
  gain on asset write-offs                                                   -10,000       -38,000 -26,000  1,000                          
  acquisition of metabasis, net of cash acquired                                                         0 0 -2,834,000                            
  acquisition of intellectual property                                                         0                              
  principal payments on equipment financing obligations                                                        0 -39,000 -42,000 -10,000 -81,000 -94,000 -135,000 -163,000 -260,000 -356,000 -397,000 -514,000 -544,000 -549,000 -544,000 -532,000 -525,000 -633,000 -699,000 -680,000 -648,000 -698,000 -726,000 -723,000 -656,000 -641,000 -693,000     
  proceeds received from sale of building and disbursed to neurogen shareholders                                                                                       
  common stock released from restriction                                                                                       
  adjustments to reconcile net income to net cash from operating activities, including effects of business acquired:                                                                                       
  write-off in-process research and development                                                                                       
  net cash provide by (used in) investing activities                                                                                       
  non-cash change in estimated fair value of contingent value rights                                                  1,153,000 -764,000                                    
  net cash (used in) operating activities of discontinued operations                                                   -200,000                                    
  net cash provide by (used in) investing activities of continuing operations                                                   3,945,000   453,000 -23,169,000 1,028,000 8,276,000 1,356,000 3,880,000 12,074,000 13,052,000 -4,231,000 3,873,000                        
  net cash from investing activities of discontinued operations                                                                                       
  net cash from financing activities of continuing operations                                                   -840,000                                    
  non-cash development milestone revenue                                                            0 0                          
  cash acquired from acquisition of neurogen                                                                                       
  net cash from financing activities of discontinued operations                                                                                       
  issuance of common stock for acquisition                                                                                       
  change in estimated fair value of contingent value rights                                                     -222,000 -679,000 1,736,000 -2,440,000 -2,460,000 -3,690,000 -552,000                            
  proceeds from sale of property and equipment and building                                                        0 384,000 -3,054,000 3,259,000 92,000 1,000 0 15,000                        
  purchases of property and equipment and building                                                                                       
  net cash from investing activities of continuing operations                                                                                       
  impairment and amortization of acquired intangible assets                                                            0                           
  depreciation and amortization of property and equipment                                                        95,000 669,000 703,000 745,000 764,000 781,000 770,000 819,000 238,000 266,000 250,000 298,000 364,000 399,000 447,000 496,000 651,000 829,000 834,000 913,000 945,000 914,000 896,000 969,000 671,000 838,000 610,000 567,000 593,000 681,000 762,000 
  non-cash lease exit and termination costs                                                                                       
  loss on asset write-offs                                                               -3,000 -30,000 137,000 -30,000 669,000 274,000 10,000 -268,000 1,013,000                
  restricted indemnity account and other                                                                                       
  cash paid for acquisition of metabasis                                                                                       
  cash acquired from acquisition of pharmacopeia                                                                                       
  acquisition of development stage asset                                                                                       
  repurchase of common stock                                                                0 0 0 -1,613,000               0 0 0 -15,867,000  
  (gain) loss on asset write-offs                                                                                       
  non-cash lease termination costs                                                                                       
  non-cash exit and restructuring costs                                                                                       
  decrease (increase) in restricted cash and investments                                                                                       
  dividend paid                                                                    0 0                  
  dividend received on treasury stock held by company                                                                    0 0                  
  conversion of 6% convertible subordinated notes into common stock:                                                                                       
  employee stock option exercises                                                                                       
  realized loss on investment                                                             -115,000 -45,000 88,000  125,000 770,000 500,000                    
  amortization of acquired intangible assets                                                              162,000 162,000                        
  gain on sale leaseback                                                                                       
  amortization of acquired technology and royalty and license rights                                                                                       
  amortization of debt discount and issuance costs                                                                                241,000 237,000 234,000 229,000 211,000 194,000  
  non-cash interest expense                                                                        501,000               
  inventories                                                                    0 0 0 930,000 2,098,000 -2,038,000 40,000 1,484,000 -327,000 180,000 -2,139,000 -1,144,000 -1,982,000 -1,508,000 -2,257,000 -1,199,000 589,000 -554,000 -1,686,000 
  restricted indemnity account                                                                -15,000 -39,000 -40,000 -68,000 -101,000 -30,000 61,000 -10,000,000                
  proceeds from equipment financing arrangements                                                                        0 485,000 147,000 398,000 629,000 0 510,000 880,000 699,000 1,770,000 540,000 323,000 0 251,000 823,000 
  decrease in other long-term liabilities                                                                        -15,000 -50,000 -29,000 -59,000 59,000 -57,000 -7,000 -30,000    -11,000 -26,000 -36,000  
  conversion of principal amount of convertible notes                                                                        128,150,000 0 1,000,000 26,100,000            
  conversion of unamortized debt issue costs                                                                        -995,000 0 -11,000 -351,000            
  conversion of unpaid accrued interest                                                                        -718,000 0 0 264,000            
  operating activities:                                                                                       
  gain on sale of avinza product line before income taxes                                                                 -122,000 1,156,000 -8,321,000 2,122,000 -6,892,000 -283,000 -310,131,000                
  (gain) loss on sale of oncology product line before income taxes                                                                                       
  amortization of deferred gain on sale leaseback                                                                 -491,000 -491,000 -491,000    -491,000                
  amortization of acquired technology and license rights                                                                     0 0 909,000  3,108,000 3,570,000 3,570,000  3,570,000 3,570,000 3,236,000 2,737,000 2,736,000  2,735,000    
  non-cash co-promote termination expense                                                                    0 0 -1,202,000 -207,000                
  investing activities:                                                                                       
  proceeds from sale of avinza product line                                                                 0 0 8,058,000 0 7,500,000 1,461,000 280,400,000                
  additional proceeds from sale of oncology product line                                                                     0                  
  decrease in restricted cash                                                                      265,000 38,814,000                
  financing activities:                                                                                       
  gain on sale of oncology product line before income taxes                                                                  685,000 -915,000                    
  employee receivable from stock option exercises                                                                      54,000 127,000                
  declaration of dividend                                                                       252,742,000                
  proceeds from sale of oncology product line                                                                                       
  payment to buy-down ontak royalty obligation                                                                            0 0 -13,000,000 -20,000,000        
  proceeds from note payable to king                                                                                       
  repurchase of company common stock                                                                    -4,075,000 -10,141,000                  
  adjustments to reconcile income to net cash from operating activities:                                                                                       
  adjustment to gain on sale of oncology product line before income taxes                                                                     2,138,000 -9,868,000 61,000                
  gain on sale of investment                                                                            -542,000 62,000          
  co-promote termination liability                                                                         3,673,000 3,066,000 136,241,000            
  decrease in restricted cash and investments                                                                                       
  gain on sale of oncology product line                                                                                       
  non-cash development milestone                                                                                       
  gain on sale of equity investment                                                                                       
  proceeds from sale of building                                                                                       
  repayment of long-term debt                                                                        -11,584,000 -85,000 -84,000 -86,000 -82,000 -79,000 -77,000 -82,000        
  receipt and retirement of common stock in settlement of pfizer development milestone                                                                                       
  receipt of exelixis, inc. common stock upon sale of equity investment in x- ceptor                                                                                       
  amortization of debt issue costs                                                                         232,000 229,000 244,000            
  gain on sale of exelixis stock                                                                         -45,000 -565,000 -343,000            
  increase in restricted investments                                                                             0    -43,000    -166,000  
  capitalized portion of payment of lasofoxifene royalty rights                                                                             0 0 -558,000        
  non-cash impact of the conversion of 6% convertible subordinated notes into common stock:                                                                                       
  non-cash interest expense converted into additional paid-in capital                                                                          3,000 57,000            
  non-cash impact of stock option exercises where cash was received subsequent to quarter-end                                                                           469,000            
  write-off of x-ceptor purchase right                                                                                  0 0 0 5,000,000  
  cumulative effect of change in accounting principle                                                                                       
  equity in loss of affiliate                                                                                  117,000 285,000 270,000 302,000 339,000 
  decrease (increase) in restricted investments                                                                                       
  payment for avinza® royalty rights                                                                                  0 0 0 -4,133,000  
  receipt of exelixis, inc. common stock upon sale of equity investment in x-ceptor                                                                                       
  amortization of debt issuance costs                                                                             263,000 258,000 254,000        
  debt conversion expense                                                                                      0 
  payment for avinza ® royalty rights                                                                                       
  payment to extend x-ceptor purchase right                                                                                      0 
  net proceeds from issuance of common stock and warrants                                                                                       
  increase in other long-term liabilities                                                                                       
  net proceeds from issuance of convertible notes                                                                                       
  conversion of zero coupon convertible senior notes to common stock                                                                                      0 
  issuance of common stock and notes for acquired technology and license rights                                                                                       
  payment for lasofoxifene royalty rights                                                                                0 -1,120,000      
  decrease in restricted investments                                                                                   -59,000    
  amortization of acquired technology, royalty, and product rights                                                                                       
  accrual of obligations for acquired technology and product rights                                                                                       
  issuance of common stock for debt conversion incentive                                                                                      0 
  issuance of common stock for acquired technology                                                                                       
  principle payments on equipment financing obligations                                                                                    -519,000 -621,000  
  amortization of acquired technology and licence rights                                                                                     2,752,000  
  changes in operating assets and liabilities net of effects from sale of manufacturing assets in 2000:                                                                                       
  net proceeds from sale of manufacturing assets                                                                                       
  accretion of debt discount and interest                                                                                       
  amortization of acquired technology                                                                                       
  decrease in other assets                                                                                       
  principle payments on equipment financing                                                                                       
  redemption of convertible debentures                                                                                       
  net proceeds from issuance of zero coupon convertible senior notes                                                                                       

We provide you with 20 years of cash flow statements for Ligand Pharmaceuticals stock, allowing you to gain comprehensive visibility into the fundamentals of the company. Our detailed breakdowns include key financial metrics such as operating cash flows, cash levels, capital expenditures, profits, stock-based compensations and profit margins. This in-depth information is essential for making informed investment decisions and understanding the financial health and performance of Ligand Pharmaceuticals stock. Explore the full financial landscape of Ligand Pharmaceuticals stock with our expertly curated income statements.

The information provided in this report about Ligand Pharmaceuticals stock is taken from www.sec.gov and many other data providers. While we have conducted our best efforts to ensure that the parsed data is accurate, we cannot guarantee its accuracy. Please use caution and understand that any consequences of its use are your own responsibility.